J D Wolchok

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
    J D Wolchok
    Ludwig Institute of Cancer Research, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 24:2174-80. 2013
  2. doi request reprint Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann N Y Acad Sci 1291:1-13. 2013
  3. doi request reprint Nivolumab plus ipilimumab in advanced melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 369:122-33. 2013
  4. doi request reprint At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
    Margaret K Callahan
    Melanoma and Sarcoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Leukoc Biol 94:41-53. 2013
  5. doi request reprint How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
    J Wolchok
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Oncol 23:viii15-21. 2012
  6. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  7. ncbi request reprint Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens
    J D Wolchok
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 1:9. 2001
  8. pmc Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Cancer Immun 10:9. 2010
  9. doi request reprint Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
  10. doi request reprint Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 11:155-64. 2010

Detail Information

Publications85

  1. doi request reprint Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
    J D Wolchok
    Ludwig Institute of Cancer Research, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 24:2174-80. 2013
    ..This analysis was carried out to evaluate the long-term survival of patients with metastatic melanoma who received ipilimumab, a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte antigen-4, in clinical trials...
  2. doi request reprint Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann N Y Acad Sci 1291:1-13. 2013
    ..Evaluation of ipilimumab is ongoing in the adjuvant setting for melanoma, and for advanced disease in nonsmall cell lung, small cell lung, prostate, ovarian, and gastric cancers. ..
  3. doi request reprint Nivolumab plus ipilimumab in advanced melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 369:122-33. 2013
    ..On the basis of their distinct immunologic mechanisms of action and supportive preclinical data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in patients with advanced melanoma...
  4. doi request reprint At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
    Margaret K Callahan
    Melanoma and Sarcoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Leukoc Biol 94:41-53. 2013
    ..See related review At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. ..
  5. doi request reprint How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
    J Wolchok
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Oncol 23:viii15-21. 2012
    ..Further research is warranted to establish how immunotherapeutic agents can be combined with conventional agents, with each other or with molecularly targeted agents such as vemurafenib, to further optimise clinical outcomes...
  6. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  7. ncbi request reprint Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens
    J D Wolchok
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 1:9. 2001
    ..These results show that immunity to TRP-2 following DNA immunization uses an IFN-gamma-dependent Th1 pathway, but immunity to gp75/TRP-1 is down-regulated by IFN-gamma...
  8. pmc Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Cancer Immun 10:9. 2010
    ..These findings support the hypothesis that ipilimumab-treated patients with advanced melanoma have similar outcomes regardless of their HLA-A*0201 status...
  9. doi request reprint Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
    ..Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required...
  10. doi request reprint Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 11:155-64. 2010
    ..Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advanced melanoma...
  11. ncbi request reprint Current topics in melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Oncol 19:116-20. 2007
    ..New approaches to melanoma are emerging. This review summarizes developments over the past 12 months...
  12. ncbi request reprint Reassessing the usual suspects causing a commotion in the blood (and vessels?)
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Biol Ther 3:124-5. 2004
  13. ncbi request reprint Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma
    Jedd D Wolchok
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Melanoma Res 13:189-96. 2003
    ..The observation of two partial responses has led to a phase II study to evaluate treatment with high dose paracetamol alone or in combination with BCNU...
  14. ncbi request reprint Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma
    Jedd D Wolchok
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 15:2044-50. 2007
    ..Mouse and human TYR DNA vaccines were found safe and induced CD8(+) T-cell responses in 7 of 18 patients. T cells recognizing a native TYR peptide had a phenotype consistent with that of effector memory cells...
  15. doi request reprint The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation
    Jedd D Wolchok
    Melanoma Sarcoma Oncology Service and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 340, New York, New York 10065, USA
    Oncologist 13:2-9. 2008
    ....
  16. ncbi request reprint Multiple pathways to tumor immunity and concomitant autoimmunity
    Mary Jo Turk
    1Weill Graduate School of Medical Sciences of Cornell University, New York, USA
    Immunol Rev 188:122-35. 2002
    ..Autoimmunity uses similar mechanisms as tumor immunity, but tumor immunity and autoimmunity can uncouple. These studies open up strategies for active immunization against cancer...
  17. doi request reprint Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs
    C A Manley
    Donaldson Atwood Cancer Clinic, The Animal Medical Center, New York, NY, USA
    J Vet Intern Med 25:94-9. 2011
    ..Metastatic disease is a common sequela for which few effective treatment options exist. Studies show that xenogeneic tyrosinase DNA vaccination yields immune responses and prolongation of survival in dogs with oral malignant melanoma...
  18. pmc Coupling and uncoupling of tumor immunity and autoimmunity
    W B Bowne
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Exp Med 190:1717-22. 1999
    ..e., antibody versus CD8(+) T cell. However, both pathways led to tumor immunity and identical phenotypic manifestations of autoimmunity...
  19. pmc Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY, USA
    Cancer Immun 9:5. 2009
    ..One patient had an increase in CD8+ IFN-gamma+ cells. This xenogeneic immunization strategy was safe and associated with minimal toxicity. There was also evidence of immune response...
  20. pmc Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma
    Jack C F Liao
    Flaherty Comparative Oncology Laboratory, Donaldson Atwood Cancer Clinic, The Animal Medical Center, New York, NY 10021, USA
    Cancer Immun 6:8. 2006
    ..Most interestingly, the onset of antibody induction in these three dogs coincides with observed clinical responses and may suggest a means to account for their long-term tumor control and survival...
  21. pmc Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation
    Robert R Jenq
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 113:1574-80. 2009
    ..In conclusion, our data suggest that KGF can function as a potent vaccine adjuvant after allo-BMT through its effects on posttransplantation T-cell reconstitution...
  22. doi request reprint Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection
    Brian A Ginsberg
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 16:4057-65. 2010
    ..To further define the optimal vaccination strategy, we conducted a pilot clinical trial comparing i.m. injection with particle-mediated epidermal delivery (PMED)...
  23. pmc Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma
    Yvonne M Saenger
    The Swim Across America Laboratory, Immunology Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer Res 68:9884-91. 2008
    ..Monoclonal antibodies should be tested as vaccine adjuvants in the treatment of cancer...
  24. ncbi request reprint Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 103:2590-7. 2005
    ..The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases...
  25. pmc CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:20410-5. 2008
    ..These data provide an immunologic rationale for the efficacy of anti-CTLA-4 therapy and call for immunotherapeutic designs that combine NY-ESO-1 vaccination with CTLA-4 blockade...
  26. doi request reprint Development of effective vaccines for old mice in a tumor model
    David N Posnett
    Dep of Medicine, Weill Medical College of Cornell University, New York, NY 10021, United States
    Vaccine 27:1093-100. 2009
    ..However, fusion constructs with Vp22 gave a strong CD4 response to B16 melanoma and the OmpA response is MHC-II dependent. Both adjuvant fusion constructs stimulated CD4 and CD8 responses otherwise diminished in old mice...
  27. ncbi request reprint Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains
    Cristina R Ferrone
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, Weill Medical and Graduate Schools of Cornell University, New York, NY 10021, USA
    Clin Cancer Res 12:5511-9. 2006
    ..We compared DNA adjuvants for their ability to enhance immunity against a poorly immunogenic self-antigen expressed by cancer...
  28. doi request reprint Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
    Miguel Angel Perales
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:2022-9. 2008
    ..Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant...
  29. pmc Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response
    Gabrielle A Rizzuto
    Departments of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 206:849-66. 2009
    ..Further, precursor frequency as an isolated variable can be exploited to augment efficacy of clinical vaccine strategies designed to activate any antigen-specific CD8(+) T cells...
  30. ncbi request reprint Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial
    Philip J Bergman
    Donaldson Atwood Cancer Clinic and Flaherty Comparative Oncology Laboratory, The E and M Bobst Hospital of the Animal Medical Center, New York, New York 10021, USA
    Clin Cancer Res 9:1284-90. 2003
    ..These studies provided the rationale for a trial of xenogeneic DNA vaccination in CMM using the human tyrosinase gene...
  31. doi request reprint Mechanisms of immunization against cancer using chimeric antigens
    Manuel E Engelhorn
    The Swim Across America Laboratory, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:773-81. 2008
    ..Therefore large fusion vector panels such as those presented here can provide information to promote the successful advancement of gene-based vaccines...
  32. ncbi request reprint DNA vaccines: an active immunization strategy for prostate cancer
    Jedd D Wolchok
    Clinical Immunology Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 30:659-66. 2003
    ..We are currently conducting a phase I trial of human and mouse PSMA DNA vaccines in patients with recurrent prostate cancer, based on preclinical experiments described below...
  33. ncbi request reprint Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine
    Francesca Orlandi
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:6195-203. 2007
    ..HER2/neu is frequently overexpressed in breast cancer. In a mouse model, vaccination with HER2/neu DNA elicits antibodies that confer partial protection against tumor challenge...
  34. ncbi request reprint A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen
    Jason S Gold
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:5188-94. 2003
    ....
  35. ncbi request reprint Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes
    Colin S B Houghton
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Vaccine 25:5330-42. 2007
    ..These data demonstrate that this approach can serve as the basis of epitope-engineering against cancer and intracellular pathogens...
  36. ncbi request reprint Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 106:2445-51. 2006
    ..Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated...
  37. ncbi request reprint Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity
    Teresa Ramirez-Montagut
    Memorial Sloan Kettering Cancer Center and the Weill Graduate School of Medical Sciences of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Oncogene 22:3180-7. 2003
    ..Vitiligo (autoimmune hypopigmentation) can be mediated by T cells, FcgammaR+macrophages and/or complement...
  38. pmc Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 5:e10436. 2010
    ..These findings provide further support for the continued development of agonist anti-GITR mAbs as an immunotherapeutic strategy for cancer...
  39. doi request reprint Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
    G D Shah
    Department of Medicine, Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 21:1718-22. 2010
    ..A secondary objective was to test the feasibility of obtaining adequate tissue before and after treatment for genetic testing...
  40. ncbi request reprint Vaccines for melanoma: translating basic immunology into new therapies
    J D Wolchok
    Clinical Immunology Service, Hematologic Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY 10021, USA
    Lancet Oncol 2:205-11. 2001
    ..Although initial clinical trials have shown the safety and immunological efficacy of vaccines for melanoma, the true clinical benefit of these strategies will only be revealed in large randomised trials...
  41. pmc Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
    Jose A Guevara-Patino
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1382-90. 2006
    ....
  42. ncbi request reprint Stage-IV melanoma and pulmonary metastases: factors predictive of survival
    Heather B Neuman
    Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H1221, New York, New York 10021, USA
    Ann Surg Oncol 14:2847-53. 2007
    ..We reviewed a contemporary, single-institution experience to evaluate the natural history of stage-IV melanoma metastatic to the lung and identify factors predictive of survival...
  43. doi request reprint Phase II study of extended-dose temozolomide in patients with melanoma
    Petra Rietschel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 26:2299-304. 2008
    ..We hypothesized that expression of methylguanine methyltransferase (MGMT) in the tumor would correlate with drug resistance to TMZ...
  44. doi request reprint Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers
    David B Page
    Melanoma Sarcoma Service, Memorial Sloan Kettering Cancer Center, NY, USA
    Immunotherapy 2:367-79. 2010
    ..The immunogram - a newly described graphical synthesis of treatment data and immune correlates in individual patients - may help us to confirm, reject or formulate new hypotheses regarding the mechanism of anti-CTLA-4 activity...
  45. pmc Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses
    Yun Lin
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, Newy York, New York 10021, USA
    Cytotherapy 11:912-22. 2009
    ..Monitoring cellular immune responses is one prerequisite for the rational development of cancer vaccines...
  46. ncbi request reprint The role of lipopolysaccharide in T-cell responses following DNA vaccination
    William G Hawkins
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 21:1548-53. 2003
    ..CD8(+) T-cell responses were readily induced in TLR4-deficient mice immunized with DNA depleted of LPS. LPS in DNA vaccines is not required for CD8(+) T-cell responses...
  47. ncbi request reprint Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue
    Roopa Srinivasan
    Swim Across America Laboratory and Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College and Graduate School of Cornell University, New York, NY 10021, USA
    Cancer Immun 2:8. 2002
    ..This represents an example of intermolecular determinant recognition, but is not simply due to epitope spreading since antibodies against the antigen targeted by DNA vaccination are not typically detected...
  48. pmc Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy
    Margaret K Callahan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Oncol 37:473-84. 2010
    ..Several immunologic endpoints have been proposed to correlate with clinical activity. This review will focus on the endpoints of immune monitoring described in studies to date and discuss future areas of additional work needed...
  49. pmc Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY 10065, USA
    Cancer Immun 10:1. 2010
    ..The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters...
  50. pmc Immune rejection of mouse tumors expressing mutated self
    Fei Duan
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:3545-53. 2009
    ..Immune modulation, such as inducing GITR signaling, is required to enhance CD8(+) T-cell responses to specific mutations and to lead to tumor rejection...
  51. pmc Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
    Peter G Maslak
    Leukemia Service, Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Blood 116:171-9. 2010
    ..Further studies are needed to establish the role of vaccination as viable postremission therapy for acute myeloid leukemia...
  52. pmc The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases
    Yvonne M Saenger
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immun 8:1. 2008
    ..Understanding the kinetics of response to ipilimumab will help clinicians to manage patients who may benefit from treatment. In this article, several cases that illustrate the kinetics of response to ipilimumab are discussed...
  53. ncbi request reprint The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword
    Alan N Houghton
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Cell 7:403-5. 2005
    ..These are surprising observations, linking antibodies of the adaptive immune system to innate immune responses that drive epithelial carcinogenesis...
  54. pmc Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination
    Polly D Gregor
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 116:415-21. 2005
    ..These results establish the basis for clinical trials to test PSMA DNA vaccines in patients with solid tumors that either express PSMA directly or that depend on normal endothelial cells expressing PSMA for their continued growth...
  55. ncbi request reprint Antigens recognized by autologous antibodies of patients with soft tissue sarcoma
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:4. 2005
    ..Further studies of these selected novel STS antigens are warranted to identify and characterize potential antigen targets expressed by STS...
  56. ncbi request reprint Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:2. 2005
    ....
  57. ncbi request reprint CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma
    Maria Lia Palomba
    Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:370-9. 2005
    ..These results show that active immunization with xenogeneic DNA vaccines can induce CD8+ T cell-dependent immunity against CD20...
  58. ncbi request reprint CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
    Polly D Gregor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:1700-8. 2004
    ..Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration...
  59. ncbi request reprint Immunity to cancer through immune recognition of altered self: studies with melanoma
    Jose A Guevara-Patino
    Memorial Sloan Kettering Cancer Center and the Weill Graduate School of Medical Sciences and Medical School of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Adv Cancer Res 90:157-77. 2003
    ..Studies examining the molecular basis for immunogenicity of conserved paralogues are facilitating the development of new strategies to rationally design vaccines that trigger adaptive immune responses to cancer...
  60. ncbi request reprint Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Clinic Immunology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:5214-20. 2003
    ..However, vaccination of patients with GD2-KLH has previously failed to induce a consistent relevant antibody response. We test here whether the use of GD2 lactone-KLH can overcome the low immunogenicity of GD2-KLH...
  61. ncbi request reprint Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma
    Wen Jen Hwu
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:3351-6. 2003
    ..To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases...
  62. ncbi request reprint Melanoma vaccines
    Miguel Angel Perales
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford I Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Cancer Invest 20:1012-26. 2002
    ..In this review, we will discuss strategies to induce active immunity against melanoma...
  63. ncbi request reprint DNA vaccines for melanoma
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Chemother Biol Response Modif 22:761-8. 2005
  64. ncbi request reprint DNA vaccines against cancer
    Rodica Stan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Hematol Oncol Clin North Am 20:613-36. 2006
    ..It gives a brief history and then discusses the proposed mechanism of action, preclinical and clinical studies, and methods of enhancing the immune responses induced by DNA vaccines...
  65. doi request reprint Radiotherapy after surgical resection for head and neck mucosal melanoma
    Abraham J Wu
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Am J Clin Oncol 33:281-5. 2010
    ..To present our single-institution experience with postoperative radiotherapy for mucosal melanoma of the head and neck...
  66. ncbi request reprint Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles
    Stacie M Goldberg
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8114-21. 2005
    ..The purpose of this study was to compare viral and plasmid DNA in combination vaccination strategies in the context of a tumor antigen...
  67. pmc Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity
    Adam D Cohen
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 66:4904-12. 2006
    ..Finally, this effect on vaccine-induced CD8(+) T-cell responses was partially independent of CD4(+) T cells (both helper and regulatory), consistent with a direct costimulatory effect on the effector CD8(+) cells themselves...
  68. ncbi request reprint DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
    Miguel Angel Perales
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:4159-67. 2006
    ..These results demonstrate that DNA immunization against tissue-restricted Ags after allogeneic T cell-depleted HSCT can induce potent antitumor effects without causing GVHD...
  69. ncbi request reprint In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring
    J Yuan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cytotherapy 8:498-508. 2006
    ..We have established a reproducible method using peptide-pulsed K562-A*0201 cells as APC to expand Ag-specific T cells in vitro. This method may be applied for monitoring T-cell responses in cancer immunotherapy clinical trials...
  70. ncbi request reprint Clinical results using biochemotherapy as a standard of care in advanced melanoma
    P B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY 10021, USA
    Melanoma Res 12:381-7. 2002
    ..The low response rate among previously treated patients indicates that biochemotherapy is not useful as second-line therapy...
  71. ncbi request reprint Persistence makes perfect: the benefits of IL-2 in adoptive immunotherapy
    G A Rizzuto
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Cytotherapy 7:391-2. 2005
  72. ncbi request reprint Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center
    P J Bergman
    Donaldson Atwood Cancer Clinic and Flaherty Comparative Oncology Laboratory, The Animal Medical Center, 510 East 62nd Street, New York, NY 10021, USA
    Vaccine 24:4582-5. 2006
    ..These studies provided the impetus for development of a xenogeneic DNA vaccine program in CMM...
  73. ncbi request reprint Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling
    Neil H Segal
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:1775-81. 2003
    ..CCS/MSP also has typical melanoma features, including immunoreactivity for S100 and HMB45, pigmentation, MITF-M expression, and a propensity for regional lymph node metastases...
  74. ncbi request reprint GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines
    Miguel Angel Perales
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cytokines Cell Mol Ther 7:125-33. 2002
    ..These results have implications for understanding early events in the immune response to DNA vaccines, and provide a basis for development of new approaches to cancer vaccines, including the use of cytokine genes as adjuvants...
  75. doi request reprint Immune regulatory antibodies: are they the next advance?
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer J 16:311-7. 2010
    ....
  76. ncbi request reprint Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications
    Y B Su
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:610-6. 2004
    ..Using an extended dosing schedule, we noted a high incidence of lymphopenia and occasional opportunistic infections (OIs). Here we report our retrospective experience in the first 97 patients...
  77. pmc OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
    Daniel Hirschhorn-Cymerman
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 206:1103-16. 2009
    ..Closer examination revealed that diminished intratumoral T reg cell levels resulted from hyperactivation and T reg cell-specific apoptosis. Thus, we propose that CTX and OX40 engagement represents a novel and rational chemoimmunotherapy...
  78. ncbi request reprint Anti-GITR antibodies--potential clinical applications for tumor immunotherapy
    David A Schaer
    Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue, New York, NY 10065, USA
    Curr Opin Investig Drugs 11:1378-86. 2010
    ..This review discusses the role of GITR as a potential target for immunomodulatory therapy, as well as the research involved in understanding the mechanisms of anti-GITR therapy and current progress in translation into the clinic...
  79. ncbi request reprint How can we tell when cancer vaccines vaccinate?
    Jedd D Wolchok
    J Clin Oncol 21:586-7. 2003
  80. ncbi request reprint Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope
    Jedd D Wolchok
    J Clin Oncol 20:3176; author reply 3176-7. 2002
  81. ncbi request reprint Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy
    Howard L Kaufman
    J Clin Oncol 24:2230-2. 2006
  82. ncbi request reprint Strategies to overcome immune ignorance and tolerance
    Miguel Angel Perales
    Memorial Sloan Kettering Cancer Center and Weill Medical School and Graduate School of Cornell University, New York, NY 10021, USA
    Semin Cancer Biol 12:63-71. 2002
    ..Crucial to these approaches is the discovery and understanding of the molecular identity of antigens and the mechanisms involved in tumor immunity. In this review, strategies to overcome immune ignorance and tolerance are discussed...
  83. doi request reprint Meeting report: fourth international congress of the Society for Melanoma Research
    David E Fisher
    Department of Pediatric Hematology Oncology and Melanoma Program, Dana Farber Cancer Institute and Children s Hospital of Boston, Boston, MA 02115, USA
    Pigment Cell Melanoma Res 21:15-26. 2008
    ..This report will highlight the major scientific themes and advances of this most successful meeting, and provide a useful perspective on the current state of melanoma research, as well as where the field should be heading...
  84. ncbi request reprint CD4 help and tumor immunity: beyond the activation of cytotoxic T lymphocytes
    Miguel Angel Perales
    Ann Surg Oncol 11:881-2. 2004
  85. ncbi request reprint Surgical management of melanoma of the gallbladder: a report of 13 cases and review of the literature
    Steven C Katz
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg 193:493-7. 2007
    ..Melanoma has the potential to spread to virtually any organ, including the gallbladder. The role of intervention in this rare entity must be based on a thorough appreciation of the underlying disease biology...